The historical rank and industry rank for Harvard Bioscience's FCF Margin % or its related term are showing as below:
FRA:HBI0'
s FCF Margin % Range Over the Past 10 Years
Min: -1.94 Med: 2.66 Max: 10.44
Current: 1.51
During the past 13 years, the highest FCF Margin % of Harvard Bioscience was 10.44%. The lowest was -1.94%. And the median was 2.66%.
FRA:HBI0's FCF Margin % is ranked better than 53.99% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.03
vs FRA:HBI0: 1.51
Harvard Bioscience FCF Margin % Related Terms
Harvard Bioscience FCF Margin % Historical Data
* Premium members only.
The historical data trend for Harvard Bioscience's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:HBI0 vs FEMY, RVP, MLSS: FCF Margin % Comparison
For the Medical Instruments & Supplies subindustry, Harvard Bioscience's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harvard Bioscience FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Harvard Bioscience's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harvard Bioscience (FRA:HBI0) has a FCF Margin % of -6.18% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Harvard Bioscience and its competitors. According to the industry distribution chart, Harvard Bioscience ranks #375 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 46%.
Is Harvard Bioscience's FCF Margin % too high?
Harvard Bioscience's current FCF Margin % is -6.18%. Based on the distribution chart, Harvard Bioscience ranks #375 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Harvard Bioscience has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Harvard Bioscience's FCF Margin % compare to FEMY and RVP?
According to the Medical Devices & Instruments industry distribution chart, Harvard Bioscience ranks #375 out of 815 companies for FCF Margin %. This puts Harvard Bioscience in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Harvard Bioscience and its competitors. Harvard Bioscience's current FCF Margin % is -6.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Bioscience stock overvalued right now?
Harvard Bioscience (FRA:HBI0) has a current FCF Margin % of -6.18%. The stock's GF Value™ is €13.30, compared to a current price of €4.08 — trading 69.3% below its estimated fair value. The current FCF Margin % is -6.18%. Harvard Bioscience's overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Harvard Bioscience (FRA:HBI0), the current FCF Margin % is -6.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harvard Bioscience (FRA:HBI0) Overvalued in 2026?
Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued.
The current stock price of €4.08 is trading 69.3% below its estimated GF Value™ of €13.30.
Key valuation signals for FRA:HBI0:
FCF Margin %: -6.18%
GF Value™: €13.30 vs. price of €4.08 (69.3% below fair value)
No single metric tells the full story. See the FRA:HBI0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
48GF Score
Get the complete analysis for FRA:HBI0
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HBI0 has been successfully added to your 
